TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to Inhaled Tobramycin. A randomized placebo-controlled double-blinded trial of azithromycin 500mg thrice weekly in combination with inhaled tobramycin

C
Clement Ren, MD

Primary Investigator

Overview

This is a study to examine the effect of combining chronic oral azithromycin with inhaled tobramycin in adolescent and adult subjects with cystic fibrosis who are chronically infected with P. aeruginosa.

Description

This study is a prospective, randomized, double-blinded, placebo-controlled trial of azithromycin 500mg taken orally thrice weekly vs. placebo in subjects with cystic fibrosis and chronic airway infection with P. aeruginosa who are utilizing chronic inhaled tobramycin therapy.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    cystic fibrosis
  • Age: Between 12 Years - 100 Years
  • Gender: All

Inclusion Criteria
Documented diagnosis of cystic fibrosis
At least two respiratory cultures growing P. aeruginosa within the last 12 months
Use of at least two cycles of inhaled tobramycin within the last 24 weeks
Off TISP and other inhaled anti-pseudomonal antibiotics for at least 2 weeks at Visit 1 and remain off of any inhaled antibiotics for an additional 2 weeks before starting inhaled tobramycin
Prior or current use of azithromycin for at least four consecutive weeks
Exclusion Criteria
Positive pregnancy test, lactating, or unwillingness to practice a pre-defined form of contraception, which includes abstinence
Inability or unwillingness to cycle off of inhaled tobramycin for one 4-week period and without Use of any additional inhaled antibiotics
Use of intravenous or oral anti-pseudomonal antibiotics within 4 weeks of screening
Use of investigational therapy within 4 weeks of screening
Use of systemic corticosteroids equivalent to a daily dose more than 10mg of prednisone
Use of nelfinavir, warfarin, haloperidol, or methadone (concern of drug interaction with azithromycin) modulator therapy within 30 days
Any other condition that, in the opinion of the site investigator, would compromise the safety of the subject or quality of the data


Additional Information:
Participants will not be paid for their participation.

Updated on 09 Mar 2024. Study ID: 1708919614

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center